InvestorsHub Logo
Followers 1
Posts 14
Boards Moderated 0
Alias Born 01/29/2014

Re: None

Saturday, 03/15/2014 9:09:56 PM

Saturday, March 15, 2014 9:09:56 PM

Post# of 750282
The timing of Germany's decision is telling. I doubt this approval came on the heels of early data only. It would have been approved long ago on that data. It's a clue, isn't it? According to NWBO's own description of the Phase III trial, the data evaluated is from 312 patients enrolled in 51 States. This excludes Europe's (Germany's) independent trial. In fact, the Phase III description, in the manner and context in which it is written implies the trials are exclusive of each other. Any thoughts fellas?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News